On September 18, 2008, Mochizuki, Akiyoshi; Kishida, Masamichi; Kanno, Hideyuki published a patent.Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate The title of the patent was Preparation of diamide derivatives as FXa inhibiting antithrombotics. And the patent contained the following:
The title compounds I [ring A = benzene ring, pyridine ring, pyrimidine ring, etc.; R1 = H, halo, alkyl, etc.; R2 = H, carboxy, carbamoyl, etc.; T1 = N(R3)CO; R3 = H, alkyl; T2 = (CH2)mCONH; m = 1 or 2; Q1 = cyclohexyl, morpholinyl, pyrrolidinyl, etc.; Q2 = single bond, 1,4-phenylene, 1,4-cyclohexylene, etc.; Q3 = (un)substituted Ph, thienyl, pyridyl, etc.] are prepared Thus, 4-[4-(2-([(5-chlorothiophene-2-carbonyl)amino]methyl]phenylcarbamoyl)phenyl)-3-oxopiperazine-1-carboxylic acid tert-Bu ester was prepared from N-(2-aminobenzyl)-5-chlorothiophene-2-carboxamide and 4-(2-[N-tert-butoxycarbonyl-N-(carboxymethyl)amino]ethylamino)benzoic acid. Compounds of this invention showed IC50 values of 1.1 nM to 8.8 nM against human FXa. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate
The Article related to amide derivative preparation fxa inhibitor antithrombotic, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: Ethyl 3-fluoro-2-methylbenzoate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics